局限性前列腺癌男性睾酮替代治疗的肿瘤学安全性:观察性研究系统综述
该系统综述纳入19项观察性研究,评估睾酮缺乏的局限性前列腺癌患者接受睾酮替代治疗(TRT)的肿瘤学安全性。主动监测者进展率0%至32%,根治性前列腺切除术后生化复发率0%至7%,放疗后0%至6%,随访长达70个月。因缺乏长期前瞻性对照数据,证据支持在低中危主动监测及治疗后 favourable 局限性疾病中谨慎使用TRT。
要点
- 主动监测患者TRT暴露后进展率0%至32%, retrospective 比较与非暴露对照组无显著差异。
- 根治性前列腺切除术后生化复发率0%至7%,放疗后0%至6%,随访至60个月。
- 证据限于回顾性观察性研究,缺乏长期前瞻性对照及生存结局数据,需谨慎选择与监测。
核心结论
- 回顾性证据支持在低中危主动监测及根治性前列腺切除术后或放疗后 favourable 局限性疾病中谨慎使用TRT,需适当PSA反应。
- 在随机对照试验数据可用前,需严格患者选择与监测以指导前列腺癌合并睾酮缺乏的安全管理。
研究设计与样本
- 遵循PRISMA指南检索Medline、EMBASE、PubMed和Scopus,检索得到4067项研究,最终纳入19项观察性研究。
- 纳入研究评估前列腺癌合并睾酮缺乏男性接受TRT的进展和生化复发,其中5项主动监测、10项根治性前列腺切除术后、6项放疗后。
主要发现
- 主动监测中TRT暴露者进展率范围为0%至32%,随访长达70个月的回顾性比较显示与非暴露对照组无显著差异。
- 根治性前列腺切除术后TRT暴露队列生化复发率范围为0%至7%,放疗(±雄激素剥夺治疗)后为0%至6%,随访至60个月。
- 因比较性研究数量不足及显著临床和方法学异质性,未进行汇总meta分析。
临床怎么用
- 对低中危主动监测及根治性前列腺切除术后或放疗后 favourable 局限性疾病合并睾酮缺乏者,可谨慎考虑TRT并确保适当PSA反应。
- 启用TRT前需严格选择患者并持续监测,直至随机对照试验数据提供更安全的管理依据。
局限性
- 缺乏长期、前瞻性、对照比较数据。
- 缺乏生存结局评估,TRT肿瘤学安全性的总体确定性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the oncological safety of testosterone replacement therapy (TRT) in hypogonadal patients with prostate cancer, as testosterone deficiency (TD) rises in prevalence with age and in prostate cancer may be treatment-related, whilst contributing to poor health outcomes. PATIENTS AND METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Medline, EMBASE, PubMed, and Scopus were searched. Studies were included assessing progression and biochemical recurrence in men with prostate cancer and TD receiving TRT. RESULTS: Searches yielded 4067 studies, of which 19 were included: five in active surveillance, 10 post-radical prostatectomy (RP), six post-radiotherapy. Pooled meta-analysis was not valid due to insufficient number of comparative studies and significant clinical and methodological heterogeneity. Progression rates on active surveillance ranged from 0% to 32% and did not differ significantly to non-exposed controls on retrospective comparison at follow-up as long as 70 months. Biochemical recurrence rates in TRT-exposed cohorts were low post-definitive treatment ranging from 0% to 7% post-RP to 0-6% post-radiotherapy (± androgen deprivation therapy) with up to 60 months of follow-up. Overall certainty of TRT oncological safety is limited by lack of long-term, prospective, controlled comparative data and lack of assessment of survival outcomes. CONCLUSIONS: Retrospective evidence supports cautious use of TRT in low-intermediate-risk disease on active surveillance and favourable localised disease post-RP or post-radiotherapy with appropriate prostate-specific antigen responses. Diligent patient selection and monitoring are required until randomised controlled trial data are available to inform safe management of TD in prostate cancer.
引用
- Santucci J, Stapleton P, Perera M, et al. Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies. BJU Int. 2025. PMID: 40747831. doi:10.1111/bju.16870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。